07:00 , Aug 6, 2007 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes Analyst picks & changes Company Bank Analyst Coverage Opinion Wk chg 8/3 cls Amgen (AMGN) Banc of America Securities William Sargent Price target Neutral -8% $50.90 Sargent raised his target to...
08:00 , Nov 7, 2005 |  BC Week In Review  |  Company News

Vernalis, Britannia, Mylan Laboratories Inc. deal

VER acquired exclusive North American marketing rights to MYL's Apokyn apomorphine injection, which is marketed to treat "off" episodes associated with PD, for $23 million in cash. VER will complete certain Phase IV...
02:36 , Nov 5, 2005 |  BC Extra  |  Company News

Vernalis Parkinson's disease deals

Vernalis (LSE:VER; VNLS) entered into two separate Parkinson's disease (PD) deals with Mylan (MYL) and Britannia (London, U.K.). VER acquired exclusive North American marketing rights to MYL's Apokyn apomorphine injection, which is marketed to treat...
07:00 , Apr 26, 2004 |  BC Week In Review  |  Clinical News

Apokyn apomorphine injection regulatory update

FDA granted marketing approval to MYL's Bertek Pharmaceuticals Inc. subsidiary (Research Triangle Park, N.C.) for its Apokyn to treat "off" episodes associated with Parkinson's disease (PD). MYL expects to launch the product by July and...
08:00 , Feb 23, 2004 |  BioCentury  |  Regulation

McClellan's waiting list

McClellan's waiting list Company Product Indication FDA action/status Week Amarin Zelapar Parkinson's disease Approvable letter 2/24/03 Antigenics Oncophage Kidney cancer, melanoma Partial clinical hold on two Ph III trials pending additional product characterization 9/3/03...